---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-050800"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:22:58.877962+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acumen appoints George Golumbeski as Chairman, replaces Sean Stalfort

## Summary
- Dr. George Golumbeski appointed as director and Chairman of Board, effective Nov 6, 2025.
- Golumbeski received initial option to buy 50,000 shares at closing price, vesting over 3 years.
- Annual retainer: $40,000 for board service plus $30,000 as Chairman.
- Board now has 8 members; Golumbeski brings 30+ years biopharma experience from Celgene, Novartis.
- Company highlights Phase 2 sabirnetug trial and Enhanced Brain Delivery program as key 2026 catalysts.

## SEC filing metadata
- accession: 0001628280-25-050800
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000162828025050800/0001628280-25-050800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000162828025050800/abos-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-050800
- JSON: https://secwatch.observer/filing/0001628280-25-050800.json
- Plain text: https://secwatch.observer/filing/0001628280-25-050800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.